The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Progression-Free Survival: Meaningful or Simply Measurable?
Abstract
The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a correspondingincreaseinoverallsurvival(OS),haveledtoapprovalofnew drugs and/or changes in standard of care. This suggests a growing belief in the oncology community that delaying progression in metastaticdiseaseisaworthygoal,evenifOSisnotimproved.Butisanew treatment that improves PFS really an advance for patients? Or is it only lowering the bar to declare active some of our much-heralded new molecular targeted therapies? We believe that as a community, this trend requires discussion and debate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
Peppercorn, J. M., Smith, T. J., Helft, P. R., DeBono, D. J., Berry, S. R., Wollins, D. S., Hayes, D. M., Von Roenn, J. H., & Schnipper, L. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1744 · Cited by 524
Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
Buyse, M., & Molenberghs, G. (1998) · Biometrics · doi:10.2307/2533853 · Cited by 425
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Buyse, M., Burzykowski, T., Carroll, K., Michiels, S., Sargent, D. J., Miller, L. L., Elfring, G. L., Pignon, J.-P., & Piedbois, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8836 · Cited by 354
Burzykowski, T., Buyse, M., Piccart-Gebhart, M. J., Sledge, G., Carmichael, J., Lück, H.-J., Mackey, J. R., Nabholtz, J.-M., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8407 · Cited by 348
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
Iwamoto, F. M., Abrey, L. E., Beal, K., Gutin, P. H., Rosenblum, M. K., Reuter, V. E., DeAngelis, L. M., & Lassman, A. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc0184 · Cited by 305
Tang, P. A., Bentzen, S. M., Chen, E. X., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1935 · Cited by 236
Burzykowski, T., Molenberghs, G., Buyse, M., Geys, H., & Renard, D. (2001) · Journal of the Royal Statistical Society Series C: Applied Statistics · doi:10.1111/1467-9876.00244 · Cited by 217
Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
Booth, C. M., Cescon, D. W., Wang, L., Tannock, I. F., & Krzyzanowska, M. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5456 · Cited by 162
Self-citationMiles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
Korn, E. L., Freidlin, B., & Abrams, J. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6056 · Cited by 148
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Soria, J., Massard, C., & Chevalier, T. L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq204 · Cited by 123
Recommendations for the assessment of progression in randomised cancer treatment trials
Dancey, J. E., Dodd, L. E., Ford, R., Kaplan, R. S., Mooney, M., Rubinstein, L., Schwartz, L. H., Shankar, L. K., & Therasse, P. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.042 · Cited by 115
Collette, L., Burzykowski, T., Carroll, K. J., Newling, D. W. W., Morris, T., & Schröder, F. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.156 · Cited by 111
Sridhara, R., Johnson, J. R., Justice, R. L., Keegan, P., Chakravarty, A. G., & Pazdur, R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp515 · Cited by 102
On the Use of Surrogate End Points in Randomized Trials
Begg, C. B., & Leung, D. H. Y. (2000) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/1467-985x.00153 · Cited by 98
Progression-free survival as a surrogate endpoint in advanced breast cancer
Miksad, R. A., Zietemann, V., Gothe, R., Schwarzer, R., Conrads‐Frank, A., Schnell‐Inderst, P., Stollenwerk, B., & Siebert, U. (2008) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462308080495 · Cited by 94
Siena, S., Peeters, M., Cutsem, E. V., Humblet, Y., Conte, P., Bajetta, E., Comandini, D., Bodoky, G., van Hazel, G., Salek, T., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604053 · Cited by 93
Ocaña, A., Amir, E., Vera, F., Eisenhauer, E. A., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0275 · Cited by 87
Self-citationSherrill, B. H., Amonkar, M. M., Wu, Y., Hirst, C., Stein, S., Walker, M. D., & Cuzick, J. M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604759 · Cited by 73
Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
Amir, E., Šeruga, B., Martínez‐López, J., Kwong, R. C., Pandiella, A., Tannock, I. F., & Ocaña, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2393 · Cited by 73
Gill, S., & Sargent, D. J. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-624 · Cited by 71
Kay, A., Higgins, J., Day, A. G., Meyer, R. M., & Booth, C. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr492 · Cited by 69
Self-citationHackshaw, A. K., Knight, A., Barrett-Lee, P. J., & Leonard, R. C. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602858 · Cited by 67
Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop☆
Bast, R. C., Thigpen, J. T., Arbuck, S. G., Basen‐Engquist, K., Burke, L. B., Freedman, R. S., Horning, S. J., Ozols, R. F., Rustin, G. J. S., & Spriggs, D. R. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.092 · Cited by 58
Cited by
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017) · BMJ · doi:10.1136/bmj.j4530 · Cited by 599
Prasad, V., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 403
Wildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S. G., Luciani, A., Curigliano, G., Extermann, M., Lichtman, S. M., Ballman, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6125 · Cited by 322
Metadata
- Authors
- Booth, C. M., & Eisenhauer, E. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-04-01
- Volume
- 30
- Issue
- 10
- Pages
- 1030-1033
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2126251787
- Cited by
- 324
- References
- 37
- FWCI
- 32.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.